Abstract:T cells engineered to express chimeric-antigen receptors (CAR-T cells) can effectively control relapsed and refractory haematological malignancies in the clinic. However, the successes of CAR-T cell therapy have not been recapitulated in solid tumours due to a range of barriers such as immunosuppression, poor infiltration, and tumour heterogeneity. Numerous strategies are being developed to overcome these barriers, which include improving culture conditions and manufacturing protocols, implementing novel CAR designs, and novel approaches to engineering the T cell phenotype. In this review, we describe the various emerging strategies to improve CAR T cell therapy for solid tumours. We specifically focus on new strategies to modulate cell function and fate that have precipitated from the growing knowledge of transcriptional circuits driving T cell differentiation, with the ultimate goal of driving more productive anti-tumour T cell immunity. Evidence shows that enrichment of particular phenotypic subsets of T cells in the initial cell product correlates to improved therapeutic responses and clinical outcomes. Furthermore, T cell exhaustion and poor persistence are major factors limiting therapeutic efficacy. The latest preclinical work shows that targeting specific master regulators and transcription factors can overcome these key barriers, resulting in superior T cell therapeutic products. This can be achieved by targeting key transcriptional circuits promoting memory-like phenotypes or sustaining key effector functions within the hostile tumour microenvironment. Additional discussion points include emerging considerations for the field such as (i) targeting permutations of transcription factors, (ii) transient expression systems, (iii) tissue specificity, and (iv) expanding this strategy beyond CAR-T cell therapy and cancer.

Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors

Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion

Single-cell ATAC-seq Maps the Comprehensive and Dynamic Chromatin Accessibility Landscape of CAR-T Cell Dysfunction.

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy

T‐cell exhaustion in CAR‐T‐cell therapy and strategies to overcome it

Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

Fundamentals to therapeutics: Epigenetic modulation of CD8+ T Cell exhaustion in the tumor microenvironment

T cell exhaustion in human cancers

TET2 regulates early and late transitions in exhausted CD8 T-cell differentiation and limits CAR T-cell function

Mechanisms of CAR T Cell Exhaustion and Current Counteraction Strategies

Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion

c-Jun overexpression in CAR T cells induces exhaustion resistance

Mechanisms of T cell exhaustion guiding next-generation immunotherapy

Enhancing the Efficacy of CAR-T Cell Therapy: A Comprehensive Exploration of Cellular Strategies and Molecular Dynamics

Transcriptional rewiring in CD8+ T cells: implications for CAR-T cell therapy against solid tumours

BATF-mediated regulation of exhausted CD8+ T-cell responses and potential implications for chimeric antigen receptor-T therapy

Exhausted T cells and epigenetic status

Repeated stimulation or tonic-signaling chimeric antigen receptors drive regulatory T cell exhaustion

The Interplay Between Epigenetic Regulation and CD8+ T Cell Differentiation/Exhaustion for T Cell Immunotherapy

Cellular and molecular waypoints along the path of T cell exhaustion